Sophia Genetics has raised $13.75M in Series B financing in a round led by Dr Mike Lynch’s Invoke Capital, Endeavour Vision and Swisscom.
Sophia Genetics is a pioneer in Data-Driven Medicine, a crossover field that requires deep expertise in Next Generation Sequencing (NGS), combined with highly accurate and scalable predictive algorithms to diagnose genetic diseases. With this investment, Sophia gains access to Invoke’s portfolio company Genalys, whose Cambridge-based mathematicians apply big data approaches to genomic information.
